Catecholamines enhance the mechanical performance of the heart by activating cardiac β-adrenergic receptors (βARs). Although cardiomyocytes co-express β~1~AR and β~2~ARs, the β~1~AR is the predominant subtype and principal driver of catecholamine-driven sympathetic responses in the healthy heart. β~1~ARs couple to a G~s~--cyclic adenosine monophosphate (cAMP)--protein kinase A (PKA) pathway that phosphorylates substrates that enhance excitation/contraction coupling and provide hemodynamic support in the setting of an acute stress. Although β~1~ARs also couple to cardioprotective G~s~-independent mechanisms such as extracellular regulated kinase (ERK) [@bib1], chronic/persistent β~1~AR activation leads to a spectrum of changes (including cardiomyocyte hypertrophy/apoptosis, interstitial fibrosis, and contractile dysfunction) that contribute to the pathogenesis of heart failure (HF) [@bib2]. βAR inhibitors that prevent maladaptive cAMP-driven βAR responses have become mainstays of HF therapy.

Although βAR activation provides hemodynamic support and compensates for the contractile dysfunction that develops in HF, chronic HF leads to a loss of cardiac reserve due to desensitization and/or down-regulation of βARs [@bib2]. Decreased β~1~AR density is a hallmark of HF, but the mechanism underlying this adaptive mechanism remains uncertain because the classic paradigms for βAR regulation are based largely on studies of the β~2~AR subtype. Current models hold that agonists stabilize βARs in an active conformation that is phosphorylated by G protein--coupled receptor kinases (GRKs). GRK-phosphorylated βARs then recruit β-arrestin, which functions both to initiate desensitization and facilitate clathrin-mediated βAR internalization [@bib3]. However, the general assumption that this mechanism applies equally to β~1~AR and β~2~AR subtypes is at odds with evidence that these receptor subtypes are regulated differently in the setting of HF; HF leads to a relatively selective down-regulation of β~1~ARs that is not accompanied by a commensurate loss of β~2~ARs [@bib4].

The prevailing assumption that decreased β~1~AR expression in the failing heart is attributable to chronic catecholamine-induced, GRK/β-arrestin--dependent receptor desensitization is also at odds with cell-based studies showing that β~1~ARs are relatively resistant to agonist-induced, GRK-dependent phosphorylation; they engage β-arrestin only weakly; and they show little-to-no agonist-induced internalization [@bib5], [@bib6]. These differences should not be surprising because β~1~AR and β~2~ARs share only 54% overall homology at the amino acid level, with sequence conservation confined largely to transmembrane/ligand-binding regions; β~1~AR and β~2~AR intracellular loops and C-termini (regions that serve as substrates for GRK phosphorylation and/or docking sites for β-arrestin) are divergent [@bib7]. This study identifies an alternative redox-activated mechanism that selectively decreases cardiomyocyte β~1~ARs.

In the course of these studies, we also identified a heretofore unrecognized property of carvedilol, a βAR inhibitor that reportedly offers survival advantages over other βAR inhibitors in the treatment of HF [@bib8]. Earlier studies have argued that this finding might be attributable to carvedilol's ancillary properties as an antioxidant [@bib9] or its unique pharmacologic profile; carvedilol acts as an inverse agonist for the βAR- G~s~-cAMP pathway (i.e., it prevents catecholaminergic-induced cardiotoxicity) and a biased agonist for β-arrestin--mediated signaling to ERK and potentially other cardioprotective pathways [@bib10], [@bib11]. Our studies show that carvedilol prevents β~1~AR redox inactivation and that it also triggers a novel β~1~AR-dependent cardioprotective mechanism. We recently found that β~1~ARs are detected as both full-length (FL) and N-terminally truncated species that differ in their signal bias to effector pathways [@bib12]. This study shows that carvedilol increases the abundance of N-terminally truncated β~1~ARs which constitutively activate protein kinase B (AKT) and confer protection against doxorubicin-induced apoptosis.

Methods {#sec1}
=======

Materials {#sec1.1}
---------

A full description of the antibodies and chemical reagents can be found in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Cardiomyocyte culture and adenoviral infections {#sec1.2}
-----------------------------------------------

Cardiomyocytes were isolated from the ventricles of 2-day-old Wistar rats by a trypsin dispersion technique using a differential attachment procedure to enrich for cardiomyocytes followed by irradiation as described previously [@bib12]. Methods to infect cardiomyocytes with adenoviruses that drive expression of FL or N-terminally truncated forms of human β~1~AR (Ad-FL-β~1~AR and Ad-Δ2-52-β~1~AR) were published previously.

Immunoblotting {#sec1.3}
--------------

Immunoblotting was performed on cell extracts according to methods described previously [@bib12] or manufacturer's instructions as detailed in the [Supplemental Methods](#appsec1){ref-type="sec"}. All results were replicated in at least 3 experiments on separate culture preparations.

Measurements of βAR density and cAMP accumulation {#sec1.4}
-------------------------------------------------

βAR density and cAMP accumulation were measured according to standard methods as described previously [@bib12].

Statistical analysis {#sec1.5}
--------------------

Results are shown as mean ± SEM and were analyzed by using Student's *t*-test or analysis of variance for multiple comparisons; p values \< 0.05 were considered statistically significant.

Results {#sec2}
=======

H~2~O~2~ decreases β~1~AR expression in cardiomyocytes {#sec2.1}
------------------------------------------------------

Reactive oxygen species (ROS) contribute to the pathogenesis of HF and other cardiomyopathic syndromes. Although oxidative stress leads to changes in signaling by many components of the G~s~/adenylyl cyclase/PKA pathway, the notion that the β~1~AR itself is a ROS-sensitive element in this signaling pathway (i.e., that a ROS-dependent event localized to the β~1~AR itself can contribute to evolution of HF) has never been considered. Our initial studies used immunoblotting to track H~2~O~2~-dependent effects on β~1~AR immunoreactivity.

Because the specificity of various commercially available anti--G protein-coupled receptor antibodies has been questioned [@bib13], [@bib14], preliminary studies were designed to rigorously characterize the anti-β~1~AR antibodies from Abcam and Santa Cruz (SC) that were used for the analysis. [Figure 1A](#fig1){ref-type="fig"} (left) shows that the Abcam anti-β~1~AR antibody detects human β~1~ARs heterologously overexpressed in rat cardiomyocytes as a major ∼69-kDa band and a minor ∼55-kDa species. We recently identified a similar immunoreactive profile for this transgene in 2 different model cell lines and showed that the ∼69-kDa species corresponds to FL fully glycosylated β~1~ARs; the ∼55-kDa species corresponds to N-terminally truncated glycosylation-defective β~1~ARs [@bib12]. We also showed that N-terminal truncation does not alter β~1~AR-binding affinity for the antagonist ligand iodocyanopindolol or lead to changes in basal cAMP/PKA or ERK; instead, the N-terminally truncated β~1~AR is stabilized in a conformation that results in enhanced agonist-dependent activation of cAMP/PKA and reduced agonist-dependent activation of ERK.Figure 1H~2~O~2~ Decreases β~1~AR Expression in Cardiomyocytes**(A)** Abcam and Santa Cruz (SC) anti--β~1~-adrenergic receptor (β~1~AR) antibodies were used to detect native or heterologously overexpressed β~1~ARs in cardiomyocytes. **(B to D)** Lysates from cardiomyocyte cultures treated with the specified H~2~O~2~ concentrations or 1 μM isoproterenol (for the indicated time intervals) were probed with the SC anti-β~1~AR antibody to track endogenous β~1~AR expression (with β-actin immunoreactivity serving as a protein loading control). Results in **D** are from a single set of gels exposed for a uniform duration, with white space inserted where data from 2 regions of the same gel were merged for presentation purposes. All results in **A to D** were replicated in 3 to 5 separate experiments. **(E)** βAR density (as defined by saturation binding experiments with ^125^I-iodocyanopindolol) in β~1~AR overexpressing cardiomyocytes treated with vehicle or 0.1 mM H~2~O~2~ for 30 min (n = 3).

The Abcam anti-β~1~AR antibody does not detect endogenous β~1~ARs in cardiomyocyte cultures ([Figure 1A](#fig1){ref-type="fig"}, left). However, consistent with previous studies showing that the SC anti-β~1~AR antibody recognizes endogenous mouse β~1~ARs in lysates from wild-type, but not β~1~AR knockout, hearts [@bib15], [@bib16], [Figure 1A](#fig1){ref-type="fig"} (right) shows that the SC anti-β~1~AR antibody detects a band corresponding to the FL-β~1~AR in uninfected rat cardiomyocyte cultures and that the abundance of this band increases in the context of β~1~AR overexpression. The SC anti-β~1~AR antibody also detects a band with considerably faster electrophoretic mobility. Although this species might represent endogenous N-terminally truncated β~1~ARs, it could not unambiguously be identified as a bona fide β~1~AR species because it does not increase with β~1~AR overexpression. Because this smaller band could represent nonspecific immunoreactivity, it is not considered further in the analysis.

Initial studies used the SC anti-β~1~AR antibody to track H~2~O~2~-dependent regulation of the native β~1~AR in cardiomyocyte cultures. [Figure 1B](#fig1){ref-type="fig"} shows that treatment with 0.1 mM H~2~O~2~ leads to a time-dependent decrease in β~1~AR immunoreactivity. The decrease in overall β~1~AR immunoreactivity is detected in cultures treated with a range of H~2~O~2~ concentrations (0.05 to 5 mM) ([Figure 1C](#fig1){ref-type="fig"}). Experiments using low H~2~O~2~ concentrations (0.05 to 0.1 mM) also captured a decrease in FL-β~1~AR electrophoretic mobility (which could suggest an H~2~O~2~-dependent increase in β~1~AR phosphorylation), as well as the accumulation of small amounts of a ∼50-kDa species that is presumed to represent a β~1~AR cleavage product. The H~2~O~2~-dependent decrease in β~1~AR immunoreactivity is specific and is not accompanied by a change in cardiomyocyte β~2~ARs ([Figure 1D](#fig1){ref-type="fig"}). Importantly, the response to H~2~O~2~ contrasts markedly with the response to chronic isoproterenol stimulation (30 to 120 min), which leads to a profound down-regulation of β~2~ARs and no change in the abundance of the β~1~AR subtype.

Because β~1~AR immunoreactivity could in theory be disrupted by an H~2~O~2~-dependent post-translational modification at the β~1~AR C-tail (which harbors the recognition epitopes for both anti-β~1~AR antibodies), we also performed radioligand binding experiments with ^125^I-iodocyanopindolol, a high-affinity βAR antagonist that does not discriminate between β~1~ARs and β~2~ARs. [Figure 1E](#fig1){ref-type="fig"} shows that this alternative method also identifies an H~2~O~2~-dependent decrease in βAR density.

The H~2~O~2~-dependent decrease in β~1~AR immunoreactivity is prevented by GF109203X and carvedilol {#sec2.2}
---------------------------------------------------------------------------------------------------

Cardiomyocytes were challenged with H~2~O~2~ in the presence of compounds that inhibit various signaling enzymes implicated as downstream components of the β~1~AR signaling response as an initial strategy to identify mechanism. Studies were performed in parallel on uninfected cardiomyocytes (to track H~2~O~2~-dependent effects on the native rat β~1~AR) as well as cardiomyocytes that heterologously overexpress human β~1~ARs. This approach allowed us to screen for possible differences in H~2~O~2~-dependent regulation of Gly^49^ (rodent) versus Ser^49^ (human) β~1~AR variants. Immunoblotting studies on overexpressed human β~1~ARs performed in parallel with Abcam and SC anti-β~1~AR antibodies also allowed us to further validate the specificity of these reagents. [Figure 2A](#fig2){ref-type="fig"} shows that H~2~O~2~ treatment leads to similar changes in native and heterologously overexpressed β~1~AR immunoreactivity. In each case, H~2~O~2~ treatment led to an initial decrease in β~1~AR electrophoretic mobility (best detected at the 30-min time point) followed by a decrease in β~1~AR immunoreactivity (detected at 60 min). [Figure 2A](#fig2){ref-type="fig"} shows that the H~2~O~2~-dependent mobility shift (at 30 min) and the decrease in β~1~AR immunoreactivity (at 60 min) are both completely abrogated by GF109203X (GFX; a general protein kinase C \[PKC\] inhibitor) but not by Gö6976 (which selectively blocks calcium-sensitive PKC isoforms or protein kinase D), the PKA inhibitor H-89, or the Src kinase inhibitor PP1.Figure 2The H~2~O~2~-dependent Decrease in β~1~AR Immunoreactivity Is Prevented by GFX or Carvedilol**(A and C)** Cardiomyocytes were pretreated for 1 h with 10 μM GF109203X (GFX), 10 μM PP1, 10 μM H89, 10 μM Gö6976, 0.1 μM propranolol (prop), 1 μM isoproterenol (Iso), 1 μM carvedilol (carv), 10 μM pindolol (pin), 10 μM timolol (tim), 10 μM atenolol (aten), or 10 μM metoprolol (met) as indicated and then challenged with vehicle or 0.1 mM H~2~O~2~ for 60 min (unless indicated otherwise). **(B)** Treatment with vehicle or the indicated concentrations H~2~O~2~ (in the absence or presence of 1 μM carvedilol) followed a 24-h pre-incubation with 100 ng/ml pertussis toxin (PTX). Experiments in **A to C** were performed in parallel on cardiomyocyte cultures that did or did not overexpress the β~1~AR transgene to compare stimulus-induced changes in native rat β~1~ARs (tracked with SC anti-β~1~AR antibody) and heterologously overexpressed human β~1~ARs (tracked with SC and/or Abcam anti-β~1~AR antibodies as indicated). Because β-actin immunoreactivity was not altered by β~1~AR overexpression, a single β-actin blot from uninfected cultures is depicted in the figures as a protein loading control. H~2~O~2~ and carvedilol-dependent changes in endogenous or heterologously overexpressed β~1~AR immunoreactivity are quantified in **A**, **right** (n = 6). **(D)** β~1~AR-overexpressing cardiomyocytes were treated for 24 h with a panel of β~1~AR ligands (at concentrations stipulated in **A**). Effects on β~1~AR transgene abundance are depicted on **top**, with results for 3 separate experiments on different culture preparations quantified on the **bottom** (\*p \< 0.05 by analysis of variance followed by a Tukey post hoc analysis). For quantification of immunoreactivity (which is expressed as arbitrary units), levels of the truncated β~1~AR species in ligand-treated cultures **(gray bars)** were normalized to the level of the truncated β~1~AR species in the corresponding vehicle-treated culture **(black bar)**, which was set to 100%. **(E)** β~1~AR-overexpressing cardiomyocytes were pretreated for 24 h with vehicle, 1 μM carvedilol, or 5 μM mitoTempo (mitoT, Sigma-Aldrich, St. Louis, Missouri) and then challenged with 100 μM H~2~O~2~ as indicated. Lysates were probed for β~1~AR immunoreactivity with β-actin immunoreactivity included as a loading control. The experiment is representative of data obtained in 4 separate experiments on different culture preparations. **(F)** Lysates from cardiomyocytes treated for 1 h with vehicle or 100 μM H~2~O~2~ (following a 1-h pretreatment with vehicle or 1 μM carvedilol as indicated) were probed for cyclic adenosine monophosphate binding response element--protein (CREB) phosphorylation and CREB protein expression. All immunoblotting data represent results obtained in 3 to 5 separate experiments. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Although there is precedent for a switch in the β~1~AR's G protein--coupling specificity from G~s~ to G~i~ under certain stimulatory conditions [@bib17], the observation that the H~2~O~2~-dependent decrease in native or heterologously overexpressed β~1~AR immunoreactivity is preserved in pertussis toxin (PTX)-pretreated cardiomyocytes ([Figure 2B](#fig2){ref-type="fig"}) indicates that H~2~O~2~-dependent regulation of β~1~ARs is not through a G~i~-dependent mechanism. Rather, these results indicate that H~2~O~2~ regulates endogenous rodent β~1~ARs and heterologously overexpressed human β~1~ARs in a similar manner and that H~2~O~2~-dependent regulation of β~1~ARs is via a mechanism that requires a novel PKC isoform activity.

H~2~O~2~ treatments were also performed in the presence of various adrenergic receptor ligands to determine whether redox sensitivity is influenced by the activation state or conformation of the β~1~AR. [Figures 2A and 2B](#fig2){ref-type="fig"} show that H~2~O~2~-dependent decreases in native and heterologously overexpressed β~1~ARs are completely abrogated by carvedilol but not by isoproterenol or propranolol. The protective effect of carvedilol is also preserved in PTX-treated cardiomyocytes, and it is specific; various other βAR antagonists (pindolol, timolol, atenolol, and metoprolol) do not share this action ([Figure 2C](#fig2){ref-type="fig"}). Studies performed on cardiomyocytes that heterologously overexpressed human β~1~ARs (where both FL and N-terminally truncated β~1~ARs species could unambiguously be tracked with the Abcam antibody) also exposed an additional effect of carvedilol to increase basal levels of the more rapidly migrating N-terminally truncated β~1~AR species ([Figure 2D](#fig2){ref-type="fig"}). This action is also unique to carvedilol; the abundance of the N-terminally truncated β~1~AR species is not influenced by other βAR ligands.

These unique actions of carvedilol to protect β~1~ARs from H~2~O~2~-dependent inactivation and increase expression of N-terminally truncated β~1~ARs are intriguing, given reports that carvedilol might offer survival advantages over other βAR blockers in patients with HF [@bib8]. Although some have argued that carvedilol might exert distinct clinical actions by virtue of its unique pharmacologic profile (carvedilol acts as an inverse agonist for the G~s~-PKA pathway but a biased agonist for non-G protein/β-arrestin--dependent signaling [@bib11]), carvedilol also possesses antioxidant properties [@bib9]. Therefore, it was important to consider whether carvedilol protects β~1~ARs from H~2~O~2~-dependent inactivation by limiting oxidative stress, in essence mimicking the actions of the mitochondrial-targeted antioxidant mitoTEMPO (Sigma-Aldrich, St. Louis, Missouri, which prevents the H~2~O~2~-depedent decrease in β~1~AR ([Figure 2E](#fig2){ref-type="fig"}). The observations that the effect of carvedilol to increase the abundance of the more rapidly migrating N-terminally-truncated β~1~AR species is not mimicked by mitoT ([Figure 2E](#fig2){ref-type="fig"}) and that carvedilol treatment does not block the H~2~O~2~ -dependent increase cAMP binding response element protein (CREB) phosphorylation at Ser^133^ (a signaling response that results from the activation of several H~2~O~2~ -sensitive signaling kinases that cooperate to phosphorylate CREB [@bib18] ([Figure 2F](#fig2){ref-type="fig"}) argue that the β~1~AR-regulatory actions of carvedilol cannot simply be ascribed to its antioxidant properties.

Doxorubicin decreases β~1~AR levels in cardiomyocytes; carvedilol prevents the doxorubicin-induced decrease in β~1~ARs {#sec2.3}
----------------------------------------------------------------------------------------------------------------------

Doxorubicin is a chemotherapeutic agent that is highly effective in the treatment of various hematologic and solid tissue malignancies. Although the anticancer effects of doxorubicin derive primarily from its actions to intercalate into nucleic acid side chains and disrupt deoxyribonucleic acid/ribonucleic acid synthesis and repair, doxorubicin treatment also leads to the generation of ROS species that contribute to doxorubicin-induced cardiotoxicity [@bib19]. We therefore examined whether doxorubicin treatment influences β~1~ARs.

[Figure 3A](#fig3){ref-type="fig"} shows that doxorubicin treatment leads to a dose-dependent decrease in FL-β~1~AR immunoreactivity and that this action is associated with the predicted defect in βAR-signaling responses; isoproterenol-dependent increases in cAMP accumulation and ERK phosphorylation are blunted in doxorubicin-treated cardiomyocytes ([Figure 3B](#fig3){ref-type="fig"}). Of note, doxorubicin specifically regulates the β~1~AR subtype; doxorubicin treatment does not lead to a change in β~2~AR immunoreactivity ([Figure 4A](#fig4){ref-type="fig"}).Figure 3Doxorubicin Treatment Leads to a Decrease in β~1~AR Expression and Action in Cardiomyocytes**(A)** β~1~AR-overexpressing cardiomyocyte cultures were treated for 24 h with doxorubicin (Dox) in the absence or presence of 1 μM carvedilol as indicated, and lysates were probed for β~1~AR expression, with β-actin immunoreactivity used as a loading control. A representative experiment is depicted on the **left**, with effects of doxorubicin (10 μM) and/or carvedilol on the abundance of the larger full-length (FL) and smaller truncated β~1~AR species quantified on the **right** (n = 7; \*p \< 0.05 by analysis of variance). **(B)** Cardiomyocytes were pretreated for 24 h with vehicle or 10 μM doxorubicin and then challenged for 5 min with vehicle or isoproterenol (1 μM, unless indicated otherwise). Doxorubicin treatment resulted in a significant decrease in isoproterenol-dependent cyclic adenosine monophosphate (cAMP) accumulation and extracellular regulated kinase (ERK) phosphorylation (p \< 0.05; n = 4). Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.Figure 4Carvedilol Activates AKT, Prevents the Doxorubicin-dependent Loss of β~1~AR Expression, and Protects Against Doxorubicin-Induced Apoptosis**(A)** Lysates from β~1~AR-overexpressing cardiomyocytes treated for 24 h with vehicle, 10 μM doxorubicin alone, or 10 μM doxorubicin plus 1 μM carvedilol were probed for β~1~AR and β~2~AR expression, protein kinase B (AKT) and ERK phosphorylation, and caspase-3 cleavage (with β-actin immunoreactivity used as a loading control). Results are representative of data obtained in 4 separate experiments on separate culture preparations. **(B)** Lysates from cardiomyocytes treated with 0.1 μM isoproterenol or 1 μM carvedilol for the indicated intervals were probed for ERK and AKT phosphorylation, with immunoreactivity for the cognate protein serving as a loading control. A representative experiment is depicted on **top,** with maximal agonist-dependent phosphorylation responses for ERK (at 5 min, n = 5) or AKT (at 30 min, n = 3) quantified at the **bottom**, with the basal value in each individual experiment set to 100% as a reference **(open bar)** and agonist-dependent increases in immunoreactivity expressed relative to basal **(shaded bars)**. Abbreviations as in [Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

The doxorubicin-dependent decrease in β~1~AR immunoreactivity is prevented by carvedilol ([Figure 3A](#fig3){ref-type="fig"}), much like the response to an acute challenge with H~2~O~2~. However, chronic 24-h doxorubicin treatment also leads to the accumulation of the smaller ∼55-kDa β~1~AR species. This band, which increases in cardiomyocytes treated with carvedilol alone, becomes prominent in cardiomyocytes treated with doxorubicin in the presence of carvedilol.

N-terminally truncated β~1~ARs that accumulate in carvedilol-treated cardiomyocytes constitutively activate AKT and confer protection against doxorubicin-induced apoptosis {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Carvedilol has been characterized as an antagonist for the classic G~s~-cAMP pathway and a biased agonist for the GRK/β-arrestin pathway that activates ERK and potentially other cardioprotective pathways [@bib11], [@bib20]; thus, the carvedilol-rescued β~1~AR could in theory confer protection against doxorubicin-induced apoptosis. In fact, [Figure 4](#fig4){ref-type="fig"} shows that doxorubicin treatment leads to the accumulation of a caspase-3 cleavage product and that the level of this apoptosis marker is reduced when doxorubicin treatment is in the presence of carvedilol. Of note, this antiapoptotic action of carvedilol is associated with a modest increase in the phosphorylation of AKT but no detectable increase in ERK phosphorylation.

The failure to identify a carvedilol-dependent increase in ERK phosphorylation was somewhat surprising, given previous evidence that carvedilol acts as a biased agonist for the β-arrestin--ERK pathway [@bib11]. However, previous conclusions were based almost exclusively on experiments performed in model cell lines that heterologously overexpress epidermal growth factor receptors; evidence that carvedilol activates ERK in cardiomyocytes is conspicuously absent. In fact, [Figure 4B](#fig4){ref-type="fig"} shows that isoproterenol induces a rapid increase in ERK phosphorylation (at 2 to 5 min), whereas carvedilol-activated β~1~ARs do not increase ERK phosphorylation under these conditions in neonatal rat cardiomyocyte cultures. Rather, carvedilol (much like isoproterenol) activates AKT; this response is detected after more prolonged agonist stimulations (at 30 min).

These results raise the intriguing hypothesis that carvedilol rescues cardiomyocytes from doxorubicin-induced apoptosis by activating a cardioprotective AKT phosphorylation pathway. Two mechanisms are possible. In theory, carvedilol might induce cardioprotection by preventing redox inactivation of FL-β~1~ARs because the carvedilol-rescued FL-β~1~ARs would be stabilized in a conformation that activates AKT. Alternatively, the actions of carvedilol to increase expression of the truncated ∼55-kDa β~1~AR species might be cardioprotective, if the N-terminally truncated β~1~AR species displays signaling bias to AKT or other antiapoptotic pathways. The N-terminally truncated Δ2-52-β~1~AR species (designed to mimic the β~1~AR cleavage product that accumulates in carvedilol-treated cardiomyocytes) was heterologously overexpressed in cardiomyocytes to resolve these alternative mechanisms. We previously showed that Δ2-52-β~1~AR overexpression does not result in changes in basal cAMP levels or ERK phosphorylation in cardiomyocytes [@bib12]. However, [Figure 5A](#fig5){ref-type="fig"} shows that Δ2-52-β~1~AR overexpression leads to the constitutive activation of AKT and reduced doxorubicin-dependent apoptosis (tracked as caspase-3 and poly \[ADP-ribose\] polymerase cleavage).Figure 5The N-terminally Truncated β~1~AR That Accumulates in Carvedilol-Treated Cardiomyocytes Constitutively Activates AKT and Confers Protection Against Doxorubicin-Induced Apoptosis**(A)** Cardiomyocytes that heterologously overexpress similar levels of FL or N-terminally truncated β~1~ARs (Δ2-52) (as validated according to both immunoblot analysis and radioligand binding with ^125^I-iodocyanopindolol, based on protocols detailed elsewhere [@bib12]) were treated for 24 h with vehicle or doxorubicin. Lysates were probed for β~1~AR expression, AKT phosphorylation, and caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage, with β-actin immunoreactivity as a loading control. A representative experiment is depicted on the **left**; results for pAKT (n = 9), caspase-3 cleavage (n = 4), or PARP cleavage (n = 6) are quantified on the **right** (with all results normalized to immunoreactivity in corresponding vehicle-treated FL-β~1~AR expressing cardiomyocytes). **(B)** Effects of PTX (100 ng/ml) on AKT phosphorylation in FL-β~1~AR or Δ2-52-β~1~AR overexpressing cardiomyocytes. The data are representative of results obtained in 3 separate culture preparations. Abbreviations as in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}.

The G protein--independent/β-arrestin--dependent pathway that links G protein--coupled receptors to ERK activations can also lead to the activation of AKT; however, a β-arrestin--dependent Δ2-52-β~1~AR--AKT activation pathway seemed unlikely given previous evidence that Δ2-52-β~1~ARs display reduced agonist-dependent activation of ERK [@bib12]. Rather, [Figure 5B](#fig5){ref-type="fig"} shows that the increase in basal AKT phosphorylation in Δ2-52-β~1~AR overexpressing cardiomyocytes is completely abrogated by PTX, implicating a PTX-sensitive G~i~ protein in this pathway. Collectively, these results identify a novel role for N-terminally truncated β~1~ARs that accumulate in carvedilol-treated cardiomyocytes as activators of a G~i~-AKT pathway and mediators of cardioprotection.

Discussion {#sec3}
==========

The factors that regulate βAR responsiveness, which provide hemodynamic support in response to stress but also contribute to the pathogenesis of HF, have been the focus of extensive investigation. The published data historically has focused on homologous desensitization mechanisms involving GRKs and β-arrestins that prevent βAR coupling to G proteins, promote βAR internalization, and terminate signaling via the cAMP pathway. However, cell-based studies showing that β~1~ARs are relatively refractory to this form of desensitization raise questions as to the mechanism underlying the defect in β~1~AR responsiveness that characteristically develops in HF [@bib5], [@bib6]. This dilemma is not necessarily resolved by studies that identify alternative mechanisms to influence cardiac catecholamine responsiveness because these mechanisms alter signaling by the β~2~AR subtype [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26]. Similarly, although there is evidence that doxorubicin treatment leads to a selective decrease in cardiac β~1~AR expression without an associated decrease in β~2~ARs [@bib27], [@bib28], these previous experiments do not specifically address the underlying mechanism (and the role of oxidative stress) because the changes in β~1~AR expression occur in the context of a doxorubicin-induced contractile defect that alone would be predicted to impair βAR responsiveness. Studies reported herein provide novel evidence that oxidative stress, a stimulus that contributes to the pathogenesis of HF, acts as a direct regulator of β~1~AR expression and catecholamine responsiveness in cardiomyocytes.

In an attempt to identify mechanisms, we found that the H~2~O~2~-dependent decrease in β~1~AR expression is abrogated by GFX and carvedilol. The mechanism underlying the protection afforded by GFX remains uncertain. Although the β~1~AR third intracellular loop contains a consensus phosphorylation motif for basophilic kinases (and could in theory serve as a substrate for PKC), phosphorylation at this site has previously been attributed to PKA (and not PKC). However, the β~1~AR extreme C-terminus conforms to a PDZ motif that interacts with synapse-associated protein SAP97 [@bib29], a scaffolding protein that serves as a platform to anchor higher order macromolecular complexes involving β~1~ARs and signaling partners such as PKC [@bib30], [@bib31]. Studies to determine whether this interaction provides a mechanism for PKC regulation of β~1~ARs and to determine the identity of the novel PKC isoform that prevents the H~2~O~2~-dependent decrease in β~1~AR levels are ongoing.

The mechanism underlying carvedilol's ability to protect β~1~ARs from H~2~O~2~-dependent inactivation also is not directly addressed by our studies but may be more explainable. Carvedilol contains a bulky aromatic amine substitution that is not present in other adrenergic ligands. Structural studies indicate that this bulky side group makes unique contacts with an extended β~1~AR ligand--binding pocket that includes the redox-sensitive cysteines in extracellular loop 2 [@bib32], the presumptive redox-sensitive molecular determinants on the β~1~AR extracellular surface. It is tempting to speculate that carvedilol prevents H~2~O~2~- or doxorubicin-dependent decreases in β~1~ARs by directly shielding these cysteines from redox inactivation, producing a conformational rearrangement of the extracellular surface so as to bury the redox-sensitive disulfide bonds within the receptor structure, or stabilizing the structure of the reduced receptor.

Previous published data showed that lipophilic ligands (e.g., alprenolol, carvedilol) act as pharmacologic chaperones to increase levels of immature, smaller 47- to 55-kDa forms of the β~1~AR that lack core glycans (and presumably represent N-terminally truncated β~1~ARs), which otherwise are retained in the endoplasmic reticulum and targeted for degradation [@bib33]; these could also explain carvedilol's actions to increase levels of the N-terminally truncated β~1~AR species. Our results suggest that levels of the N-terminally truncated β~1~AR (the minor β~1~AR species in most cardiomyocyte preparations) are limited by endoplasmic reticulum quality control systems that recognize truncated β~1~ARs as improperly or incompletely folded proteins; these findings also suggest that carvedilol stabilizes N-terminally truncated β~1~ARs in a conformation that facilitates their exit from the endoplasmic reticulum and trafficking to their site of action.

Carvedilol abrogates H~2~O~2~- and doxorubicin-induced decreases in FL-β~1~AR expression and enhances expression of a cardioprotective N-terminally truncated β~1~AR species; these findings suggest 2 possible mechanisms that could contribute to carvedilol's antiapoptotic/cardioprotective actions in animal models of ischemia/reperfusion injury and acute myocardial infarction [@bib34] as well as to its actions to protect against doxorubicin-induced cardiotoxicity in the clinic [@bib35], [@bib36], [@bib37], [@bib38]. First, the carvedilol-rescued FL-β~1~AR would be stabilized in a conformation that activates cardioprotective signaling pathways but not cAMP. Although previous studies in model cell lines showed that carvedilol-activated β~1~ARs stimulate ERK, our studies identified AKT as a downstream effector of carvedilol-activated β~1~ARs in cardiomyocytes. These findings resonate with the recent observation that carvedilol activates a β~1~AR/β-arrestin--dependent pathway that stimulates the processing of certain micro--ribonucleic acids that activate AKT in cardiomyocytes [@bib39]. Second, N-terminally truncated β~1~ARs that constitutively activate AKT accumulate in carvedilol-treated cardiomyocytes and would protect against doxorubicin-induced apoptosis. Of note, carvedilol is reported to protect bone marrow stem cells against H~2~O~2~-induced cell death, attenuate 6-hydroxydopamine--induced cell death in PC12 cells, and prevent doxorubicin-induced cardiomyopathy, in each case in association with the activation of AKT [@bib40], [@bib41], [@bib42]. These results suggest that a β~1~AR-AKT pathway plays a more general role in mediating carvedilol's cytoprotective actions in different cell types.

The observation that the actions of carvedilol to prevent redox inactivation of FL-β~1~ARs and enhance expression of N-terminally truncated β~1~ARs (i.e., promote the accumulation of 2 β~1~AR species that activate a cardioprotective AKT pathway) are not shared by various other β-blockers also deserves emphasis. Although the notion that β-blockers provide clinical benefit for patients with HF is not disputed, uncertainties as to whether β-blockers exert a class effect (i.e., can be used interchangeably in the treatment of patients with HF), or whether carvedilol offers superior clinical efficacy, has never been fully resolved. The incremental survival advantage afforded by carvedilol over metoprolol in COMET (Carvedilol Or Metoprolol European Trial) (one of the few published large-scale, head-to-head randomized comparisons of carvedilol vs. another β-blocker) has variably been attributed to carvedilol's unique pharmacologic actions or should be dismissed as a feature of the study design and a possible difference in the efficacy of β~1~-blockade [@bib8], [@bib43]. Our results identify a unique β~1~AR-dependent cardioprotective action of carvedilol that may be pertinent to this controversy because it is predicted to offer a meaningful survival advantage.

Finally, the observation that N-terminally truncated β~1~ARs constitutively activate AKT through a PTX-sensitive G~i~-dependent mechanism was surprising. Although there are isolated reports that describe βAR signaling via PTX-sensitive G~i~ proteins, β~1~AR-dependent responses traditionally have been attributed to G~s~ or G protein--independent, β-arrrestin--dependent pathways. However, there is recent evidence that carvedilol stabilizes β~1~ARs in a conformation that initiates Gα~i~-dependent β-arrestin biased signaling responses [@bib44] and that β-arrestin recruitment may be dispensable for βAR activation of ERK in certain model cell types [@bib45], [@bib46]. Collectively, these results serve to challenge prevailing dogma regarding the molecular transducers that link βARs to cardioprotective ERK or AKT pathways. The role of GRKs or β-arrestins in H~2~O~2~- or doxorubicin-mediated decreases in β~1~AR signaling or the signaling responses evoked by N-terminally truncated β~1~ARs that attenuate doxorubicin-induced apoptosis are the focus of ongoing studies.

Conclusions {#sec4}
===========

These studies identify a novel redox-induced mechanism that controls cardiac β~1~AR responsiveness. The studies also identify a novel β~1~AR regulatory action for carvedilol, providing a framework to use carvedilol as a prototype for the design of next-generation β~1~AR-selective compounds with unique β~1~AR regulatory cardioprotective properties.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** A decrease in β~1~AR expression and defective catecholamine-dependent responses are hallmarks of HF, but the precise mechanisms that drive HF-induced changes in β~1~AR responsiveness remain uncertain because β~1~ARs are relatively refractory to agonist-dependent desensitization in cell-based studies. Similarly, βAR inhibitors have become mainstays in the therapy of HF; however, the factors that contribute to their seemingly counterintuitive cardioprotective actions (whether they act by inhibiting maladaptive responses induced by sustained β~1~AR activation or conversely by resensitizing cardiac βARs and restoring catecholamine responses) remain uncertain. This study expands current β~1~AR signaling paradigms to show that oxidative stress disrupts β~1~AR-dependent signaling responses in cardiomyocytes. We also show that certain βAR inhibitors protect β~1~ARs from redox inactivation and promote the accumulation of an N-terminally truncated form of the β~1~AR that displays a unique cardioprotective action.**TRANSLATIONAL OUTLOOK:** Current guidelines recommend βAR inhibitors as first-line HF therapy, but controversies as to whether carvedilol (a nonspecific α~1~, β~1~, and β~2~AR blocker with unique pharmacologic properties) offers survival advantage over other currently available βAR blockers have never been fully resolved. This study identifies novel cardioprotective actions for carvedilol that are not shared by other βAR blockers, showing that carvedilol prevents redox inactivation of the β~1~AR, and it promotes the accumulation of N-terminally truncated β~1~ARs that constitutively activate AKT and prevent doxorubicin-induced apoptosis. These unique β~1~AR-regulatory cardioprotective properties are predicted to offer meaningful survival advantages.
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